Autoimun Lupus

Autoimun Lupus. Systemic lupus erythematosus (SLE) is the most common type of lupus SLE is an autoimmune disease in which the immune system attacks its own tissues causing widespread inflammation and tissue damage in the affected organs It can affect the joints skin brain lungs kidneys and blood vessels.

As an autoimmune disease lupus occurs when your immune system attacks healthy tissue in your body It&#39s likely that lupus results from a combination of your genetics and your environment It appears that people with an inherited predisposition for lupus may develop the disease when they come into contact with something in the environment that can trigger lupus.

Autoimmune Diseases of Rheumatoid Arthritis and Lupus

Lupus is a chronic (longterm) disease that can cause inflammation and pain in any part of your body It’s an autoimmune disease which means that your immune system — the body system that usually fights infections — attacks healthy tissue instead Lupus most commonly affects your Skin Joints.

Systemic Lupus Erythematosus (SLE) CDC

OverviewAbout Rheumatoid Arthritis and LupusNeed For New TherapiesAmp ApproachImmunology Database and Analysis PortalGovernanceBudget 6 YearsNational Institutes of Health (NIH) 10 biopharmaceutical companies and multiple nonprofit organizations launched an unprecedented new publicprivate partnership in February 2014 Managed through the Foundation for the NIH (FNIH) the Accelerating Medicines Partnership® (AMP®) program brings highlevel government industry and nonprofit foundation partners together to identify and validate the most promising biological targets for therapeutics The partners designed a bold milestonedriven research plan to tackle the challenge for the autoimmune diseases of rheumatoid arthritis and systemic lupus erythematosus (lupus) as well as for Alzheimer’s disease and type 2 diabetes One of the features that makes this publicprivate partnership unique is that AMP data is publicly accessible to the broad biomedical community for further research The Phase This fact sheet addresses the AMP research plan for rheumatoid arthritis and lupus Rheumatoid arthritis (RA) and lupus are relatively common severe disorders About 15 million people or about 06 percent of the US adult population have rheumatoid arthritis Estimating how many people in the US have lupus is difficult because symptoms vary widely and onset is often hard to pinpoint Both conditions are autoimmune diseases that occur when the immune system mistakenly attacks parts of the body that it is designed to protect They represent just two of a larger number of autoimmune disorders including multiple sclerosis Crohn’s disease ulcerative colitis type 1 diabetes and psoriasis These diseases share common flaws in immune function and regulation leading to inflammation that destroys tissues They can last a lifetime cause severe disability greatly affect quality of life and are associated with increased risk of death Treatments for these diseases typically have been aimed at decreasing inflammation and pain by slowing down tissue damage and reducing complications Most people with RA have only a partial response to available drugs and many only respond to drugs for a limited period of time In the case of lupus no effective targeted therapies exist for the most severe forms of the disease Research is needed to better understand the underlying disease process and identify parts of the immune system that aren&#39t functioning correctly This insight will help reveal the most promising new biological targets for drug development and match existing drugs to patients with specific molecular profiles who are most likely to benefit This project is analyzing at the single cell level tissue and blood samples from people with RA and lupus to pinpoint genes proteins biological pathways and signaling networks This type of analysis will allow insights into key aspects of diseases processes and allow comparisons between diseases The project will explore differences between those RA patients who respond to therapies and those who do not and will provide a better systems level understanding of disease mechanisms in both RA and lupus This knowledge is essential for the development of targeted therapies and for the application of existing and future therapies to appropriate patient populations The partnership is using several new or developing technologies to analyze information from single cells and groups of cells involved in autoimmunity collecting tissue samples including synovium (the tissue that lines joints) from people with RA and kidney from people with lupus for molecular analysis developing computational tools to integrate different data types to characterize molecular pathways and making the data available to the broad research community for further analysis through dbGaP (rheumatoid arthritis lupus) and ImmPort(link is external)(accession SDY997 SDY998) The first datasets were released in 2018 Researchers mining the data can seek to identify treatment targets to develop medicines for diseases of interest The data also has potential implications for precision medicine as AMP RA/SLE researchers identify differences in the pathways active in the tissue of different patients The steering committee (SC) for RA and lupus is comprised of representatives from NIH FNIH and participating companies and nonprofit organizations The SC meets on a regular basis and is responsible for monitoring progress towards milestones The SC operates under the direction of the overall AMP Executive Committee comprised of representatives from NIH FNIH participating companies the Food and Drug Administration and nonprofit organizations ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the US Department of Health and Human Services.